All posts by: Michael Zand

About Michael Zand

Bayer Buys More Crispr Stock After Celgene Sells – Barron’s

Continue reading

2018-01-31 NEWS

Barron’s

Bayer Buys More Crispr Stock After Celgene Sells
Barron’s
Both Bayer and Celgene invested in Crispr before the company went public. A Bayer unit agreed in December 2015 to create a joint venture to discover and commercialize therapeutics to treat blood disorders, blindness and heart disease, other indications
Reviewing Crispr Therapeutics (NASDAQ:CRSP) and Iqvia (IQV)The Ledger Gazette
Should You Invest in CRISPR Therapeutics AG (CRSP)? A Look at the Insider TrendsStockNewsGazette
Analysts’ Views: Government Properties Income Trust (GOV) and Crispr Therapeutics Ag (CRSP)Post Registrar
Madison.com –Post Analyst –TrueBlueTribune
all 33 news articles »
Continue reading

2018-01-31 NEWS

Barron’s

Bayer Buys More Crispr Stock After Celgene Sells
Barron’s
A Bayer unit invested $12 million more in the Swiss firm right before a rally that saw the stock rocket. By. Ed Lin. Jan. 31, 2018 1:29 p.m. ET. By. Ed Lin. Jan. 31, 2018 1:29 p.m. ET. Crispr Therapeutics’ largest shareholder just invested another $12
Here’s Why Editas Medicine Rose as Much as 15.7% YesterdayMotley Fool
Reviewing Crispr Therapeutics (NASDAQ:CRSP) and Iqvia (IQV)The Ledger Gazette
Should You Invest in CRISPR Therapeutics AG (CRSP)? A Look at the Insider TrendsStockNewsGazette
Post Registrar –TrueBlueTribune
all 31 news articles »
Continue reading

2018-01-31 NEWS

Researchers Identify Novel Drivers of Cancer Stem Cells That Lead to Colon Cancer Development and Growth
Newswise (press release)
Newswise — Wilmington, Del., Jan 30, 2018 – In breakthrough colon cancer research, scientists at Christiana Care Health System’s Center for Translational Cancer Research (CTCR) of the Helen F. Graham Cancer Center & Research Institute have discovered

and more »